Testing Xanamem for Alzheimer's Disease-related dementia

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the safety, tolerability, and efficacy of Xanamem, a potential treatment for mild to moderate dementia due to Alzheimer's Disease. Participants aged 50 and older will be randomly assigned to receive either 10 mg of Xanamem or a placebo daily for 36 weeks in a double-blind manner. The study aims to determine if Xanamem can improve symptoms associated with early stages of Alzheimer's Disease. Eligible participants must meet specific cognitive and diagnostic criteria to ensure they have dementia likely due to Alzheimer's.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Male or female aged 50 years or older, inclusive at the time of Screening.
* Clinical syndrome of mild or moderate dementia, likely to be due to AD in the opinion of the Investigator, at Screening, including meeting the following criteria:

  1. Clinical Dementia Rating (CDR) global score of 0.5 to 1.0
  2. Mini-mental state examination (MMSE) score of 18 to 26
  3. Magnetic resonance imaging (MRI) or computerized tomography (CT) scan within 1 year prior to randomization that excludes alternative diagnoses for dementia such as large stroke, likely vascular dementia, brain tumor, subdural hematoma, or other non-AD dementia type findings
  4. Positive plasma AD biomarker signature at Pre-screening, comprising fasting levels of a tau species protein.
* If receiving symptomatic AD medications, the dosing regimen must have been stable for 3 months prior to Screening.
* Has a consenting trial partner who, in the Investigator's judgment, has frequent and sufficient contact with the participant to be able to provide accurate information as to the participant's cognitive and functional abilities. The trial partner must be available to provide information to the Investigator and trial site staff about the participant and agrees to attend all trial site visits in person for scale completion. A trial partner should be available for the duration of the trial. The measure of adequate availability will be at the Investigator's discretion.
* Participants must be able to comfortably abstain from caffeine intake for 4 hours prior to scheduled cognitive assessments.
* Smokers are eligible if they are able to comfortably abstain from nicotine / tobacco products for 2 hours prior to scheduled cognitive assessments.
* Must provide written informed consent to participate in the trial and be willing and able to participate for the maximum of 9 months of treatment and up to 11.5 months of site visits.

Exclusion Criteria:

* Use of anti-amyloid or anti-tau antibody within 6 months.
* Diagnosis of a non-AD dementia including traumatic brain injury.
* Diagnosis of an active major mental illness of concern in the opinion in the Investigator, including major depressive disorder, bipolar illness, or schizophrenia.
* Participation in another clinical trial of a drug or device
* Has a body mass index or body weight that will interfere with participation in the trial, including inadequate venous access to complete the trial assessments, to be determined at the discretion of the Investigator.
* Previous clinically significant systemic illness or infection, including test positive COVID-19, within the past 4 weeks prior to Screening.
* Clinical diagnosis of Type I or Type II diabetes requiring insulin.
* Exhibit physical, cognitive, or language impairments, in the opinion of the Investigator, of such severity as to adversely affect the validity of the data derived from the neuropsychological tests.
* Trial participants with evidence of current infection with HIV, hepatitis B, or hepatitis C.
* Participants with a history of clinically significant drug abuse or addiction in the past 2 years
* Evidence or history of alcohol abuse

Where it's running

• ACW Investigative Site 218
  Carlsbad, California, United States Recruiting
• ACW Investigative Site 213
  Orange, California, United States Recruiting
• ACW Investigative Site 209
  Sherman Oaks, California, United States Recruiting
• ACW Investigative Site 211
  Denver, Colorado, United States Recruiting
• ACW Investigative Site 208
  Englewood, Colorado, United States Recruiting
• ACW Investigative Site 203
  Delray Beach, Florida, United States Recruiting

Study contacts

• Study coordinator: Global Program Lead
• Email: clinicaltrials@actinogen.com.au
• Phone: +61 2 8964 7401

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Caregiver-assisted pain management for older adults with dementia

  This study is testing a program that trains caregivers to help older adults with mild to moderate dementia manage their chronic pain better.

  Recruiting Duke University · Durham, North Carolina · NCT06854718

• Using paper and smartphone aids to help memory in Alzheimer's and dementia patients

  This study is testing whether using paper or smartphone memory aids can help people with mild cognitive impairment and mild dementia remember things better in their daily lives.

  Recruiting at 2 sites Baylor University · Austin, Texas and 2 other locations · NCT06444841

• Blood biomarker cohort for memory disorders in older adults

  This observational cohort will collect blood samples and brain imaging data from adults 50+ with memory disorders and a small group of healthy young adults to help find biomarkers.

  Recruiting Yonsei University · Seoul, Seodamun-gu · NCT07880275

• Tau changes after hip or knee replacement surgery

  Researchers will see if brain tau changes after hip or knee surgery and whether these changes relate to inflammation and thinking abilities.

  Recruiting Uppsala University Hospital · Uppsala · NCT07871487

• Low-Dose Whole-Brain Radiation Therapy With HeLaXON 1X in Mild Alzheimer's Dementia

  This study will test whether a low-dose brain radiation treatment using HeLaXON helps people with mild Alzheimer's dementia improve or stabilize thinking and daily function.

  Recruiting ReadyCure Inc. · Cheonan, Chungcheongnam-do · NCT07863011

• Cervical lymphatic surgery to see if it helps people with mild Alzheimer’s

  We’re testing a surgical approach in people with mild Alzheimer’s to see if creating alternative neck lymph drainage routes can affect brain biomarkers and daily function.

  Recruiting at 2 sites Maliszewski Daniel · Gdansk and 1 other locations · NCT07857759

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.